Johnson & Johnson sees device slowdown in third quarter
This article was originally published in Clinica
Executive Summary
Competition from Boston Scientific in the drug-eluting stent market took its toll on Johnson & Johnson's medical device and diagnostic sales growth in the third quarter. Revenues rose by just 3.6% operationally, to $4bn - although positive currency effects helped boost reported growth to 7%. A year earlier, third-quarter growth was 16.3% operationally and 20.3% on a reported basis.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.